Investors in Bioxodes include:
Life Sciences Research Partners (LSRP)
LSRP is a Belgian not-for-profit organization formerly known as the D. Collen Research Foundation. It was founded by Emeritus Professor Désiré Collen in 1988 to carry out, promote and support scientific research in general and biomedical and biotechnological research in particular. Désiré Collen holds a M.D. degree and Ph.D in Chemistry from Katholieke Universiteit Leuven (KUL), Belgium. He served as Director of the Molecular Cardiovascular Medicine Group (comprising the Center for Molecular and Vascular Biology of the KUL and the Vesalius Research Centre of the Flanders Institute for Biotechnology in Leuven, Belgium until September 2008. He has research interests in translational research in biopharmaceutical drug development. His team initially developed t-PA, still the most effective drug for thrombolytic therapy of acute myocardial infarction. Dr. Collen has co-authored over 650 research papers and has received four honorary doctorates and several scientific awards including the Francqui Prize (Belgium), the Prix Louis Jeantet de Médecine (Switzerland), the Bristol-Myers-Squibb award for Cardiovascular Research (USA), and the Health Prize of the Interbrew-Baillet Latour Fund (Belgium) (jointly with P. Carmeliet). He was the Founder and, until August 2008, Chief Executive Officer of ThromboGenics, NV, a biopharmaceutical drug development company listed on Euronext Brussels. He serves as the Chairman of the Board of ThromboGenics NV until 2013. LSRP is represented on the board of Bioxodes by Chris Buyse.
Pierre Drion is a Belgian philanthropist, financier and science enthusiast. His main interests in research range from biotechnology to sociology. Pierre Drion is an emblematic figure in the Belgian financial world. Some of the most important financial transactions in Belgium bear his trademark. He was formerly CEO of Petercam, one of Belgian’s principal investment banks active in three main areas: private and institutional asset management, corporate finance and stock market transactions. Mr Drion is also a former Chairman of Spadel and Unibra, Vice-Chairman of the Belgian Association of Bankers and Exchange Brokers, as well as Director of a number of other companies including Axa Belgium, Electrabel, Neuhaus and Luxempart. Today, he is still member of the board of a number of companies and he remains a Senior Adviser at Petercam. Pierre Drion is Chairman of the ULB Foundation, established in 2008 to promote scientific research at the Université Libre de Bruxelles by organizing fundraising activities in Belgium and abroad.
Mr. Olivier van der Rest is a high profile Belgian businessman holding the chairmanship of Catalpa sa/nv as well as of Aliaxis sa/nv, one of Belgium’s largest companies, where has been a Director since 2003. The Aliaxis Group is a leading global manufacturer and distributor of primarily plastic fluid handling systems used in residential and commercial construction, as well as in industrial and public infrastructure applications with annual turnover in the region of €2.5 billion.
Jean Stéphenne was Chairman of GSK Biologicals until his retirement in 2012. He began his career with SmithKline-Rit, where he movedup the ranks and steered the company through a series of mergers to create one of the leading global vaccine companies. He also served as the President of UWE (Union Wallonne des Entreprises – the employers’ association of Wallonia) and was its Chairman from 1997 to 2000. He is an Independent Chairman of BESIX Group SA/NV and is also the Chairman of TiGenix N.V. He is also Chairman of Vesalius Biocapital, Nanocyl, Bepharbel, BioWin and Welbio, and is a Board member of BNP Paribas Fortis, VBO/FEB, Groupe Bruxelles Lambert (GBL) and OncoDNA. Jean Stéphenne was named Baron by King Albert II of the Belgians in 2000 in recognition of his leading contribution to R&D and the pharmaceutical industry in Belgium.
Financière Spin-off Luxembourgeoise SA
Financière Spin-off Luxembourgeoise is the venture capital investment vehicle of the Investsud Group founded in 2006 by Investsud and the Walloon Government to invest in the capital of young and innovative technology companies. INVESTSUD has invested over 160 million euros in more than 300 companies. The Financière Spin-off Luxembourgeoise invests in seed and start-up stage companies not limited to specific industry sectors. The fund often participates in financing rounds in combination with one or more other investors including founders, 3Fs, business angels, private funds and other public or private funds and has made a number of investments in biotechnology. The fund is represented on Bioxodes’ board by Pierre Detrixhe.